# Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

> **NCT04464226** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 402 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Darolutamide (Nubeqa, BAY1841788)

## Key facts

- **NCT ID:** NCT04464226
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-20
- **Primary completion:** 2028-06-26
- **Final completion:** 2028-06-26
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04464226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04464226, "Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04464226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*